Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14451 - 14475 of 15153 in total
MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
Investigational
ATIR101 is a haploidentical, naïve cell-enriched T-cell therapy.
Investigational
ssCART-19 cells consist of autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6).
Investigational
Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.
Investigational
Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) is a stem cell therapy used to treat limbal stem cell deficiencies.
Investigational
Investigational
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
HLX-58 is an investigational monoclonal antibody targeted against claudin 18.2.
Investigational
SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).
Investigational
rAAV1-CB-hAAT is a recombinant adeno-associated virus alpha 1-antitrypsin vector.
Investigational
BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational
Investigational
Investigational
Investigational
Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).
Investigational
Zinlirvimab is under investigation in clinical trial NCT03707977 (Dual Bnab Treatment in Children).
Investigational
Ubamatamab is under investigation in clinical trial NCT03564340 (Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers).
Investigational
Visugromab is under investigation in clinical trial NCT06059547 (Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer).
Investigational
Sibeprenlimab is under investigation in clinical trial NCT05248659 (Phase 2/3 Open-label Trial of Sibeprenlimab in the Treatment of Immunoglobulin a Nephropathy).
Investigational
Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)).
Investigational
Rilvegostomig is under investigation in clinical trial NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (Artemide-biliary01)).
Investigational
Displaying drugs 14451 - 14475 of 15153 in total